EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 370 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research MOST POPULAR Professor Ian Tomlinson: “Philanthropy is priceless to science” June 3, 2021 Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer August 20, 2018 Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease... June 19, 2019 Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients... July 9, 2026 Load more HOT NEWS Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in... Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials Obesity May Help Tumors Survive and Grow, Mouse Study Suggests
